polyvalent melanoma vaccine

A cancer vaccine composed of whole irradiated heterologous melanoma cells or antigens shed from multiple human melanoma cell lines, designed to express a broad array of shared melanoma-associated antigens. The polyvalent nature refers to the inclusion of multiple tumor antigens (such as MAGE-A3, MelanA, gp100, tyrosinase, melanocortin 1 receptor, and tyrosinase-related protein 2), aiming to stimulate a robust cytotoxic T-cell immune response against diverse tumor cell populations. This immune activation can inhibit tumor proliferation and induce tumor cell death. Early versions used whole cells; later formulations (e.g., seviprotimut-L) use shed antigens with adjuvants like alum or interleukin-2 liposomes. The primary indication is for the treatment or prevention of recurrence in patients with advanced or resected melanoma[1][3][4][5].

Other names

whole-cell melanoma vaccineprototype polyvalent melanoma vaccine